Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apixaban Length-Of-Stay Pulmonary Embolism Study - Hospital Admissions (ALPHA-PE)

NCT03595891 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT03595891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03595891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apixaban Length-Of-Stay Pulmonary Embolism Study - Hospital Admissions (ALPHA-PE)
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Completed
Start date
January 20, 2017
Completion date
January 29, 2021
Enrollment
660 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary embolism (pe), pulmonary thromboembolism